SBIOvsBBPETF Comparison
VS
ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Products ETF (BBP) belong to the same industry segment: Tomorrow's Treatments. SBIO's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, BBP's top sector exposures are Healthcare. SBIO is more expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.34% for BBP. SBIO is up 4.3% year-to-date (YTD) with +$62M in YTD flows. BBP performs better with 28.1% YTD performance, and +$66M in YTD flows. Run a side-by-side ETF comparison of SBIO and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
SBIO vs BBP performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/23/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | SBIO BBP | -11.00%-2.17% | -17.10%+5.26% | +4.30%+28.10% | +26.73%+41.42% | +130.96%+121.19% | +19.37%+99.68% |
| Flows | SBIO BBP | -$10M+$5M | +$21M+$26M | +$62M+$66M | +$79M+$78M | +$45M+$83M | +$6M+$76M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | SBIO BBP | +31.85%+28.19% | +32.35%+26.47% | +31.52%+25.00% | +34.22%+26.86% |
| Max drawdown | SBIO BBP | -29.19%-8.70% | -29.19%-9.59% | -42.12%-25.54% | -52.50%-37.61% |
| Max drawdown duration | SBIO BBP | 65d65d | 65d48d | 331d292d | 1479d586d |
Trading data
SBIO | BBP | |
Last sale 10/26/2026 at 1:30 PM | $53.78 | $102.33 |
| Previous close 10/23/2026 | $53.38 | $102.07 |
| Consolidated volume 10/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
SBIO | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/26/2026 at 1:30 PM
Live
Closed
SBIO | BBP | |
|---|---|---|
| Last price | $53.78 | $102.33 |
| 1D performance | +0.74% | +0.26% |
| AuM | $183.99 M | $127.72 M |
| E/R | 0.5% | 0.34% |
Characteristics
SBIO | BBP | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | ALPS | VIRTUS Investment Partners |
| Benchmark | S-Network Medical Breakthroughs Index | LifeSci Biotechnology Products Index |
| N° of holdings | 104 | 66 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 30, 2014 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
SBIO
USA
89.31%
Other
10.69%
BBP
USA
85.98%
Other
14.02%
Sectors
SBIO
Healthcare
100.01%
Other
-0.01%
BBP
Healthcare
98.44%
Other
1.56%
Advertisement
Diversification
SBIO
Total weight of top 15 holdings out of 15
41.55%
BBP
Total weight of top 15 holdings out of 15
31.08%
Top 15 holdings
Data as of August 31, 2026
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
BBP
Moderna, Inc.
3.58%
Crinetics Pharmaceuticals, Inc.
2.94%
Omeros Corp.
2.49%
Iovance Biotherapeutics, Inc.
2.36%
Verastem, Inc.
2.15%
Precigen, Inc.
1.99%
Halozyme Therapeutics, Inc.
1.84%
Zai Lab Ltd.
1.82%
Kiniksa Pharmaceuticals International Plc
1.81%
Kura Oncology, Inc.
1.72%
BeOne Medicines Ltd.
1.70%
Rigel Pharmaceuticals, Inc.
1.69%
Nuvation Bio, Inc.
1.69%
ACADIA Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
Frequently asked questions about SBIO and BBP
How have the SBIO and BBP ETFs performed in 2026?
As of October 23, 2026, SBIO is up 4.3% year-to-date (YTD), while BBP has returned 28.1%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: SBIO or BBP?
Year-to-date, the SBIO ETF saw +$62M in flows, compared to +$66M for BBP.
Which ETF is more volatile: SBIO or BBP?
Over the past year, SBIO had a volatility of 32.35%, while BBP experienced 26.47%.
Which ETF is bigger: SBIO or BBP?
As of October 23, 2026, SBIO holds $183.99 M in assets under management (AUM), while BBP manages $127.72 M.
What sectors do the SBIO and BBP ETFs invest in?
SBIO leans toward sectors like Healthcare. Meanwhile, BBP focuses on Healthcare.
What are the top holdings of the SBIO ETF and BBP ETF?
SBIO top holdings include Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc.. BBP holds in its top three: Moderna, Inc., Crinetics Pharmaceuticals, Inc. and Omeros Corp..
Which ETF is more diversified: SBIO or BBP?
SBIO holds 104 securities with 41.55% of its assets in the top 15. BBP has 66 securities and a top 15 weight of 31.08%.
Advertisement
Latest news about SBIO & BBP
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
